1. 1. Zamani B, Moeini Taba SM, Shayestehpour M. Systemic lupus erythematosus manifestation following COVID-19: A case report. J Med Case Rep. 2021;15(1):1-4. [
DOI:10.1186/s13256-020-02582-8] [
PMID] [
]
2. Zamani B, Shayestehpour M, Esfahanian F, Akbari H. The study of factors associated with pregnancy outcomes in patients with systemic lupus erythematosus. BMC Res Notes. 2020;13(1):1-6. [
DOI:10.1186/s13104-020-05039-9] [
PMID] [
]
3. Moustafa AT, Moazzami M, Engel L, Bangert E, Hassanein M, Marzouk S, et al. Prevalence and metric of depression and anxiety in systemic lupus erythematosus: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(1):84-94. [
DOI:10.1016/j.semarthrit.2019.06.017] [
PMID]
4. Iwata S, Tanaka Y. Association of viral infection with the development and pathogenesis of systemic lupus erythematosus. Front Med. 2022;9:849120. [
DOI:10.3389/fmed.2022.849120] [
PMID] [
]
5. Shayestehpour M, Zamani B. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur Rev Med Pharmacol Sci. 2020;24(22):11474.
6. Shayestehpour M, Zamani B. Systemic lupus erythematosus and varicella‐like rash following COVID‐19 in a previously healthy patient. J Med Virol. 2021;93(5):2599. [
DOI:10.1002/jmv.26838] [
PMID] [
]
7. Zhao J, You X, Zeng X. Research progress of BK virus and systemic lupus erythematosus. Lupus. 2022;31(5):522-31. [
DOI:10.1177/09612033221084259] [
PMID]
8. Quaglia M, Merlotti G, De Andrea M, Borgogna C, Cantaluppi V. Viral infections and systemic lupus erythematosus: New players in an old story. Viruses. 2021;13(2):277. [
DOI:10.3390/v13020277] [
PMID] [
]
9. Jog NR, James JA. Epstein Barr virus and autoimmune responses in systemic lupus erythematosus. Front Immunol. 2021;11:623944. [
DOI:10.3389/fimmu.2020.623944] [
PMID] [
]
10. Blazsek A, Sillo P, Ishii N, Gergely Jr P, Poor G, Preisz K, et al. Searching for foreign antigens as possible triggering factors of autoimmunity: Torque teno virus DNA prevalence is elevated in sera of patients with bullous pemphigoid. Exp Dermatol. 2008;17(5):446-54. [
DOI:10.1111/j.1600-0625.2007.00663.x] [
PMID]
11. Siahpoush M, Noorbazargan H, Kalantari S, Shayestehpour M, Yazdani S. Coinfection of torque teno virus (TTV) and human papillomavirus (HPV) in cervical samples of women living in Tehran, Iran. Iran J Microbiol. 2022;14(2):181-5. [
DOI:10.18502/ijm.v14i2.9185] [
PMID] [
]
12. Moghimi M, Shayestehpour M, Doosti M, Vasmehjani AA, Ahmadi AS, Akhondi-Meybodi M. Prevalence of torque teno virus in healthy individuals and those infected with hepatitis C virus living in Yazd, Iran. Caspian J Intern Med. 2020;11(2):199-204.
13. Webb B, Rakibuzzaman A, Ramamoorthy S. Torque teno viruses in health and disease. Virus Res. 2020;285:198013. [
DOI:10.1016/j.virusres.2020.198013] [
PMID]
14. Swedan S, Al-Saleh D. Transfusion transmitted virus and dengue virus among healthy blood donors: A prevalence report from Jordan. Biomol Biomed. 2023;23(3):450-6. [
DOI:10.17305/bjbms.2022.7832]
15. Gergely Jr P, Pullmann R, Stancato C, Otvos Jr L, Koncz A, Blazsek A, et al. Increased prevalence of transfusion-transmitted virus and cross-reactivity with immunodominant epitopes of the HRES-1/p28 endogenous retroviral autoantigen in patients with systemic lupus erythematosus. Clin Immunol. 2005;116(2):124-34. [
DOI:10.1016/j.clim.2005.04.002] [
PMID]
16. Costa MR, Costa IP, Devalle S, Castro AR, Freitas SZ. Prevalence and genetic diversity of torque teno virus in patients with systemic lupus erythematosus in a reference service in Mato Grosso do Sul. Rev Bras Reumatol. 2012;52(1):49-54. [
DOI:10.1590/S0482-50042012000100006] [
PMID]
17. Petri M. Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin. 2005;31(2):245-54. [
DOI:10.1016/j.rdc.2005.01.009] [
PMID]
18. Seemayer C, Viazov S, Neidhart M, Brühlmann P, Michel B, Gay R, et al. Prevalence of TTV DNA and GBV-C RNA in patients with systemic sclerosis, rheumatoid arthritis, and osteoarthritis does not differ from that in healthy blood donors. Ann Rheum Dis. 2001;60(8):806-9. [
DOI:10.1136/ard.60.8.806] [
PMID] [
]
19. Shirai T, Hirose S. Molecular pathogenesis of SLE. Springer Semin Immunopathol. 2006;28(2):79-82. [
DOI:10.1007/s00281-006-0032-5] [
PMID]
20. Kooistra K, Zhang YH, Henriquez NV, Weiss B, Mumberg D, Noteborn MH. TT virus-derived apoptosis-inducing protein induces apoptosis preferentially in hepatocellular carcinoma-derived cells. J Gen Virol. 2004;85(6):1445-50. [
DOI:10.1099/vir.0.79790-0] [
PMID]
21. Table1. Frequency of TTV among SLE patients and the control group
22. Group TTV Positive TTV Negative P Value
23. SLE 43 (74.1%) 15 (25.8%) .03
24. Control 33 (56.9%) 25 (43.1%)
25. Table 2. Frequency of TTV among SLE patients according to the clinical signs, lupus activity, and disease duration
26. Characteristic TTV Positive N(%) TTV
27. Negative N(%) P Value
28. Clinical sign Musculoskeletal involvement 35 (73) 13 (27) .09
29. Skin lesion 21 (70) 9 (30) .14
30. Renal manifestation 14 (70) 6 (30) .17
31. Hematological manifestation 17 (74) 6 (26) .19
32. Lupus activity 32 (74) 11 (26) .048
33. Disease duration (mean year ± sd) 6.3±3.5 5.9±3.7 0.97